Acute Myeloid Leukemia
| TREATMENT REGIMENS | |||||
|---|---|---|---|---|---|
| Hydroxyurea | |||||
| AML non M3 | |||||
| 7+3 | |||||
| HIDAC (ARA-C HD CALGB) | |||||
| Midostaurin + chemotherapy (FLT3 mutation) | |||||
| Enasidenib | |||||
| Azacitidine SC | |||||
| FLAG-IDA | |||||
| Cytarabine SC | |||||
| Azacitidine PO | |||||
| AML M3 | |||||
| Lo-Coco | |||||
| Arsenic Trioxide | |||||
| TREATMENT REGIMENS | |||||
|---|---|---|---|---|---|
| Hydroxyurea | |||||
| AML non M3 | |||||
| 7+3 | |||||
| HIDAC (ARA-C HD CALGB) | |||||
| Midostaurin + chemotherapy (FLT3 mutation) | |||||
| Enasidenib | |||||
| Azacitidine SC | |||||
| FLAG-IDA | |||||
| Cytarabine SC | |||||
| Azacitidine PO | |||||
| AML M3 | |||||
| Lo-Coco | |||||
| Arsenic Trioxide | |||||
Groupe d'étude en oncologie du Québec